EUVIMEDEUVIMED entdecken
CrossrefInfokarte

HFpEF without conventional risk factors: a clue to cardiac amyloidosis – diagnosis of 1q21-amplified systemic AL amyloidosis with low-burden plasma cell dyscrasia: a case report

Himalini Subbiah, Steve Thomas, Siva Prakash, S. Vaishnavi, Vengatesan Kowshik, RB Sudagar Singh

Romanian Medical Journal · 2026-09-30 · 73 (3) · 386

DOI: 10.37897/rmj.2026.3.2 ↗
AbstractBibliografische Angaben

Abstract

Light-chain (AL) amyloidosis results from a clonal plasma cell dyscrasia producing misfolded immunoglobulin light chains and may involve multiple organs, including the heart. Cardiac involvement may present as heart failure with preserved ejection fraction (HFpEF) and restrictive cardiomyopathy. We report a 46-year-old woman with no known comorbidities who presented with bilateral leg edema and progressive dyspnea. Cardiac MRI, performed because of disproportionate clinical findings in the absence of conventional HFpEF risk factors, revealed diffuse subendocardial late gadolinium enhancement, raising suspicion of cardiac amyloidosis. Congo red–positive abdominal fat pad biopsy confirmed amyloidosis, and subsequent hematologic evaluation demonstrated low-burden plasma cell dyscrasia with 10% bone marrow plasma cells, an abnormal free light-chain ratio, and 1q21 amplification. The patient received six cycles of cyclophosphamide, bortezomib, and dexamethasone followed by autologous stem cell transplantation, achieving hematologic remission with resolution of cardiac symptoms. This case highlights the importance of considering cardiac amyloidosis in unexplained HFpEF without conventional risk factors and the diagnostic value of cardiac MRI.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →